TABLE 2.
Partial listing of cell therapy product requests and treatment indications
| Cell product* | Treatment indication or objective |
|---|---|
| Cardiac stem/progenitor cells | Cardiac regeneration in acute myocardial infarction |
| Mesenchymal stem cells* | Repair cardiac damage in patients after myocardial infarction Sickle cell disease |
| Autologous CD34+ stem cells | Intermittent claudication |
| Autologous marrow MNCs* | Cardiac repair during left ventricular assisted device placement Stroke Left-ventricular function after acute myocardial infarction Treatment of traumatic brain injury |
| Cytomegalovirus (CMV), adenovirus, and EBV-specific cytotoxic T lymphocytes (PB-derived) | Prevent and treat viral infection (CMV, EBV, or adenovirus) Treatment of refractory posttransplant lymphoproliferative disease |
| Autologous mature apoptotic dendritic cells with human immunodeficiency virus (HIV)-1 | Therapeutic autologous vaccine for HIV-1 infected patients |
| Dendritic cells antisense and oligodeoxyribonucleotides | Preserving residual β cell mass in Type 1 diabetes |
| Allogeneic (haploidentical) natural killer cells | Control residual viral infection |
| Vaccine-human fetal lung-derived fibroblast cell line | Non–small cell lung cancer |
| Human leukemic T-cell line | Prostate cancer |
| B95-8 EBV LCL line (reagent) | Expand EBV-specific cytotoxic T lymphocytes to treat lymphoma and nasopharyngeal carcinoma |
| Human chronic myeloid leukemia–derived cell line | Treatment of persistent or relapsed B-lymphoid malignancies |
| Autologous LMP-1 and LMP-2–specific cytotoxic T lymphocytes | Treatment of EBV positive Hodgkin’s and non-Hodgkin’s lymphomas |
| Dendritic cells loaded with killed autologous chronic lymphocytic leukemia cells | Therapeutic vaccination of chronic lymphocytic leukemia patients |
| Natural killer-92 cell line | Treatment of advanced lymphomas and leukemias |
| Natural killer cells (UCB-derived) | Treatment of myeloid leukemia |
| Allogeneic (leukapheresed) natural killer cells | Postautologous stem cell transplant for patients at risk of relapse |
| Allo-depleted donor leukocytes | Enhance immune reconstitution |
| Multivalent virus-specific cytotoxic T lymphocytes (UCB-derived) | Immune reconstitution of cord blood transplant patients |
| Allogeneic T-cell-depleted progenitor cells (PB-derived) | Improve immune reconstruction posttransplant |
| Hematopoietic progenitor stem cells (UCB-derived) | Marrow reconstitution |
| CD4+/CD25+ T regulatory cells (PB-derived) | Prevent graft-vs.-host disease (GVHD) and maintain graft-versus-leukemia |
| Allogeneic EBV-LCL cell line | Natural killer cell expansion to reduce GVHD and enhance graft-versus-tumor after nonmyeloablative allogeneic hematopoietic cell transplant |
| T-regulatory cells (UCB-derived) | Decrease GVHD and enhance engraftment |
| Skeletal myoblasts | Translational development (cardiac) |
| Stem cells (adipose-derived) | Translational development (ischemia) |
| Pancreatic islets cells | Translational development to improve digestion process closed system (diabetes) |
*
Multiple applications are grouped by cell product.
EBV = Epstein-Barr virus; PB = peripheral blood; UCB = umbilical cord blood.